NDC product
Tiagabine Hydrochloride
NDC 0093-8072 · Teva Pharmaceuticals USA, Inc.
Key facts
| Product NDC | 0093-8072 |
|---|---|
| Proprietary name | Tiagabine Hydrochloride |
| Nonproprietary name | Tiagabine Hydrochloride |
| Substances | TIAGABINE HYDROCHLORIDE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Application number | NDA020646 |
| Pharmacologic classes | Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE] |
| Marketing start | Mar 9, 2018 |
| Marketing end | Oct 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory